{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Small+Cell+Prostate+Cancer&page=6", "query": { "condition": "Small Cell Prostate Cancer", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 222, "total_pages": 23, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Small+Cell+Prostate+Cancer&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Small+Cell+Prostate+Cancer&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-28T17:01:09.940Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05283330", "title": "Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cervical Cancer", "Breast Cancer", "Colon Cancer", "NSCLC", "mCRPC (Metastatic Castration-resistant Prostate Cancer)", "Glioblastoma", "Nonsmall Cell Lung Cancer" ], "interventions": [ { "name": "²¹²Pb-DOTAM-GRPR1", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Orano Med Theranostics, SAS", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2022-12-22", "completion_date": "2032-05", "has_results": false, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-10-28T17:01:09.940Z", "location_count": 8, "location_summary": "Chicago, Illinois • Iowa City, Iowa • Lexington, Kentucky + 3 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Glen Burnie", "state": "Maryland" }, { "city": "Glen Burnie", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05283330" }, { "nct_id": "NCT00739453", "title": "A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "OSI-906", "type": "DRUG" }, { "name": "erlotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 95, "start_date": "2008-10-23", "completion_date": "2012-03-03", "has_results": false, "last_update_posted_date": "2024-11-20", "last_synced_at": "2026-10-28T17:01:09.940Z", "location_count": 3, "location_summary": "Aurora, Colorado • Baltimore, Maryland • Detroit, Michigan", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00739453" }, { "nct_id": "NCT03333616", "title": "Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Genitourinary Cancer", "Adrenocortical Carcinoma", "Non-urothelial Bladder", "Non-urothelial Upper Tract", "Penile Cancer", "Non-adenocarcinoma Prostate Cancer", "Refractory Germ-cell", "High Grade Neuroendocrine Carcinoma/Small Cell Carcinoma" ], "interventions": [ { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2017-12-28", "completion_date": "2027-06-28", "has_results": false, "last_update_posted_date": "2026-07-23", "last_synced_at": "2026-10-28T17:01:09.940Z", "location_count": 6, "location_summary": "La Jolla, California • Atlanta, Georgia • Boston, Massachusetts + 2 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03333616" }, { "nct_id": "NCT05914116", "title": "A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "DB-1311", "type": "DRUG" }, { "name": "Lopinavir and Ritonavir Tablets", "type": "DRUG" }, { "name": "itraconazole", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "DualityBio Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 862, "start_date": "2023-08-17", "completion_date": "2028-05", "has_results": false, "last_update_posted_date": "2026-10-21", "last_synced_at": "2026-10-28T17:01:09.940Z", "location_count": 28, "location_summary": "Tucson, Arizona • Los Angeles, California • Santa Monica, California + 21 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05914116" }, { "nct_id": "NCT05047536", "title": "KZR-261 in Subjects With Advanced Solid Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced/Metastatic Solid Tumor" ], "interventions": [ { "name": "KZR-261", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kezar Life Sciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2021-09-30", "completion_date": "2025-01-17", "has_results": true, "last_update_posted_date": "2025-12-19", "last_synced_at": "2026-10-28T17:01:09.940Z", "location_count": 12, "location_summary": "Los Angeles, California • Tampa, Florida • Atlanta, Georgia + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05047536" }, { "nct_id": "NCT07424547", "title": "Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer", "Solid Tumor Cancer", "Advanced Metastatic Cancer", "Prostate", "Small Cell Lung Cancer", "Ovarian Cancer", "Breast Cancer" ], "interventions": [ { "name": "SYS6043", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Conjupro Biotherapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 386, "start_date": "2026-03-03", "completion_date": "2030-04", "has_results": false, "last_update_posted_date": "2026-04-07", "last_synced_at": "2026-10-28T17:01:09.940Z", "location_count": 5, "location_summary": "Plantation, Florida • Austin, Texas • San Antonio, Texas + 1 more", "locations": [ { "city": "Plantation", "state": "Florida" }, { "city": "Plantation", "state": "Florida" }, { "city": "Austin", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07424547" }, { "nct_id": "NCT00667641", "title": "Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Colorectal Cancer", "Head and Neck Cancer", "Lung Cancer", "Melanoma (Skin)", "Ovarian Cancer", "Pancreatic Cancer", "Prostate Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "bortezomib", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Medicine and Dentistry of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2007-03", "completion_date": "2009-02", "has_results": false, "last_update_posted_date": "2011-05-10", "last_synced_at": "2026-10-28T17:01:09.940Z", "location_count": 1, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00667641" }, { "nct_id": "NCT02740985", "title": "A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Malignancies", "Non-Small Cell Lung Cancer (NSCLC)", "Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC)", "Colorectal Carcinoma (CRC)" ], "interventions": [ { "name": "AZD4635", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Abiraterone Acetate", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Oleclumab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 313, "start_date": "2016-06-17", "completion_date": "2023-03-31", "has_results": false, "last_update_posted_date": "2023-05-26", "last_synced_at": "2026-10-28T17:01:09.940Z", "location_count": 17, "location_summary": "Fayetteville, Arkansas • Fresno, California • Denver, Colorado + 14 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Fresno", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Daytona Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02740985" }, { "nct_id": "NCT04592237", "title": "Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Aggressive Variant Prostate Carcinoma", "Castration-Resistant Prostate Carcinoma", "Metastatic Prostate Carcinoma", "Metastatic Prostate Neuroendocrine Carcinoma", "Metastatic Prostate Small Cell Carcinoma", "Stage IV Prostate Cancer AJCC v8" ], "interventions": [ { "name": "Cabazitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cetrelimab", "type": "BIOLOGICAL" }, { "name": "Niraparib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 120, "start_date": "2020-12-29", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-10-28T17:01:09.940Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04592237" }, { "nct_id": "NCT06287463", "title": "Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "RAF Mutation", "RAS Mutation", "NF1 Mutation", "Non-Small Cell Lung Cancer", "Pancreatic Ductal Adenocarcinoma", "Melanoma", "BRAF Gene Mutation", "CRAF Gene Mutation", "Castration-Resistant Prostate Cancer (CRPC)" ], "interventions": [ { "name": "DCC-3084", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Deciphera Pharmaceuticals, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2024-05-14", "completion_date": "2026-02-13", "has_results": false, "last_update_posted_date": "2026-03-05", "last_synced_at": "2026-10-28T17:01:09.940Z", "location_count": 9, "location_summary": "Los Angeles, California • San Francisco, California • Denver, Colorado + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06287463" } ] }